Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find Radio Compass News for Maribavir

    Client Email Product

    Maribavir

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Formulations

    GLOBAL SALES INFORMATION

    PATENTS

    DIGITAL CONTENT

    PharmaCompass
    Product SearchProduct Search
    API SUPPLIERS
    API Suppliers

    API Suppliers

    2
    US DMFs Filed

    US DMFs Filed

    0

    CEP/COS Certifications

    CEP/COS Certifications

    0

    JDMFs Filed

    JDMFs Filed

    0

    Other Certificates

    Other Certificates

    0

    Other Suppliers

    Other Suppliers

    2
    API REF. PRICE (USD / KG)

    0

    API Market Place

    0

    INTERMEDIATES

    0

    DOSSIERS // FDF
    USA (Orange Book)

    USA (Orange Book)

    1
    Europe

    Europe

    0

    Canada

    Canada

    1
    Australia

    Australia

    0

    South Africa

    South Africa

    0

    Uploaded Dossiers

    Uploaded Dossiers

    0

    GLOBAL SALES (USD Million)

    U.S. Medicaid

    0

    Annual Reports

    0

    FDF Market Place

    0

    EXCIPIENTS

    0

    PATENTS & EXCLUSIVITIES

    USFDA Orange Book Patents

    1

    USFDA Exclusivities

    2
    DIGITAL CONTENT

    Blog #PharmaFlow

    0

    News

    26
    REF STANDARD

    EDQM

    0

    USP

    0

    JP

    0

    Other Listed Suppliers

    0

    SERVICES

    0

    Full View ScreenFull Screen View
    Takeda Announces China NMPA Approval of LIVTENCITY for the Treatment of CMV
    Takeda Announces China NMPA Approval of LIVTENCITY for the Treatment of CMV

    https://www.businesswire.com/news/home/20231221976317/en

    BUSINESSWIRE
    21 Dec 2023
    Share Share
    Takeda Pharmaceuticals' Livtencity (maribavir) Approved In Europe
    Takeda Pharmaceuticals' Livtencity (maribavir) Approved In Europe

    https://www.ema.europa.eu/en/documents/overview/livtencity-epar-medicine-overview_en.pdf

    EMA
    05 Jul 2023
    Share Share
    Takeda Pharmaceuticals' Livtencity (Maribavir) Receives Approval in Europe
    Takeda Pharmaceuticals' Livtencity (Maribavir) Receives Approval in Europe

    https://www.ema.europa.eu/en/documents/overview/livtencity-epar-medicine-overview_en.pdf

    EMA
    17 Mar 2023
    Share Share
    Takeda’s Phase 3 AURORA Study Provides Evidence of Maribavir’s Effect in CMV
    Takeda’s Phase 3 AURORA Study Provides Evidence of Maribavir’s Effect in CMV

    https://www.businesswire.com/news/home/20221219005011/en

    BUSINESSWIRE
    19 Dec 2022
    Share Share
    NICE recommends LIVTENCITY for the treatment of adults with post-transplant CMV
    NICE recommends LIVTENCITY for the treatment of adults with post-transplant CMV

    https://bionj.org/news/pr-newswire-global?rkey=20221208EN60190&filter=16221

    BIONJ
    09 Dec 2022
    Share Share
    Eli Lilly's Livtencity (maribavir) Receives Approval in the Europe
    Eli Lilly's Livtencity (maribavir) Receives Approval in the Europe

    https://www.ema.europa.eu/en/documents/overview/livtencity-epar-medicine-overview_en.pdf

    EMA
    24 Nov 2022
    Share Share
    First oral treatment approved for post-transplant refractory cytomegalovirus
    First oral treatment approved for post-transplant refractory cytomegalovirus

    https://www.europeanpharmaceuticalreview.com/news/176332/first-oral-therapy-approved-post-transplant-refractory-cmv/

    EUROPEANPHARMACEUTICALREVIEW
    11 Nov 2022
    Share Share
    EC Approves maribavir for the Treatment of Adults With CMV Infection
    EC Approves maribavir for the Treatment of Adults With CMV Infection

    https://www.takeda.com/newsroom/newsreleases/2022/european-commission-ec-approves-livtencitytm-maribavir/

    PRESS RELEASE
    11 Nov 2022
    Share Share
    Takeda Receives Positive CHMP Opinion for Maribavir CMV
    Takeda Receives Positive CHMP Opinion for Maribavir CMV

    https://www.businesswire.com/news/home/20220915006148/en

    BUSINESSWIRE
    16 Sep 2022
    Share Share
    Takeda Presents New Exploratory Analysis Showing Patients Treated LIVTENCITY
    Takeda Presents New Exploratory Analysis Showing Patients Treated LIVTENCITY

    https://www.businesswire.com/news/home/20220422005076/en

    BUSINESSWIRE
    22 Apr 2022
    Share Share
    Takeda’s Phase III CMV infection trial of Livtencity meets primary goal
    Takeda’s Phase III CMV infection trial of Livtencity meets primary goal

    https://www.clinicaltrialsarena.com/news/takeda-cmv-livtencity-trial/

    CLINICALTRIALSARENA
    10 Dec 2021
    Share Share
    Takeda’s Phase III CMV infection trial of Livtencity meets primary goal
    Takeda’s Phase III CMV infection trial of Livtencity meets primary goal

    https://www.clinicaltrialsarena.com/news/takeda-cmv-livtencity-trial/

    CLINICALTRIALSARENA
    09 Dec 2021
    Share Share
    Takeda’s LIVTENCITY Available for Certain Individuals Ages 12 Years and Older
    Takeda’s LIVTENCITY Available for Certain Individuals Ages 12 Years and Older

    https://www.businesswire.com/news/home/20211202005653/en

    BUSINESSWIRE
    02 Dec 2021
    Share Share
    Takeda’s LIVTENCITYTM Approved by FDA in CMV; & more
    Takeda’s LIVTENCITYTM Approved by FDA in CMV; & more

    https://www.businesswire.com/news/home/20211123006185/en

    BUSINESSWIRE
    23 Nov 2021
    Share Share
    Takeda's Livtencity gets US nod for post-transplant CMV infection
    Takeda's Livtencity gets US nod for post-transplant CMV infection

    https://www.firstwordpharma.com/story/5447931

    FIRSTWORDPHARMA
    23 Nov 2021
    Share Share
    Fierce Pharma Asia—Takeda's cell, gene therapy deals; BMS-BeiGene Abraxane brawl
    Fierce Pharma Asia—Takeda's cell, gene therapy deals; BMS-BeiGene Abraxane brawl

    https://www.fiercepharma.com/pharma-asia/fierce-pharma-asia-takeda-s-cell-gene-therapy-deals-bms-beigene-abraxane-brawl

    Angus Liu FIERCEPHARMA
    15 Oct 2021
    Share Share
    FDA's ADAC unanimously backs Takeda's drug for post-transplant cytomegalovirus
    FDA's ADAC unanimously backs Takeda's drug for post-transplant cytomegalovirus

    https://endpts.com/fdas-antimicrobial-adcomm-unanimously-backs-takedas-drug-for-post-transplant-cytomegalovirus/

    Z. Brennan ENDPTS
    08 Oct 2021
    Share Share
    FDA panel backs Takeda's maribavir in transplant patients with CMV infection
    FDA panel backs Takeda's maribavir in transplant patients with CMV infection

    https://pharmaphorum.com/news/fda-panel-backs-takedas-cmv-drug-for-transplant-patients/

    PHARMAPHORUM
    08 Oct 2021
    Share Share
    HRSA orders Boehringer Ingelheim to comply with 340B drug pricing
    HRSA orders Boehringer Ingelheim to comply with 340B drug pricing

    https://www.healthcarefinancenews.com/news/hrsa-orders-boehringer-ingelheim-comply-340b-drug-pricing

    Susan Morse HFN
    07 Oct 2021
    Share Share
    FDA offers support for Takeda's potential cytomegalovirus drug
    FDA offers support for Takeda's potential cytomegalovirus drug

    https://endpts.com/fda-offers-support-for-takedas-potential-cytomegalovirus-drug-ahead-of-adcomm/

    Z. Brennan ENDPTS
    07 Oct 2021
    Share Share
    Takeda's maribavir clears cytomegalovirus infections in phase 3
    Takeda's maribavir clears cytomegalovirus infections in phase 3

    https://www.fiercebiotech.com/biotech/takeda-s-maribavir-clears-cytomegalovirus-infections-phase-3

    Nick Paul Taylor FIERCEBIOTECH
    12 Feb 2021
    Share Share
    Takeda’s Maribavir Phase 3 Clinical Trial Met Primary Endpoint of Superiority
    Takeda’s Maribavir Phase 3 Clinical Trial Met Primary Endpoint of Superiority

    https://www.businesswire.com/news/home/20210212005087/en

    BUSINESSWIRE
    11 Feb 2021
    Share Share
    New Phase 3 Data Show TAK-620 (maribavir), an Investigational Drug
    New Phase 3 Data Show TAK-620 (maribavir), an Investigational Drug

    https://www.takeda.com/newsroom/newsreleases/2020/new-phase-3-data-show-tak-620-maribavir-an-investigational-drug-for-the-treatment-of-transplant-recipients-with-refractoryresistant-cytomegalovirus-cmv-infections-meets-primary-endpoint/

    PRESS RELEASE
    04 Dec 2020
    Share Share
    New Phase 3 Data Show TAK-620 (maribavir), an Investigational Drug
    New Phase 3 Data Show TAK-620 (maribavir), an Investigational Drug

    https://www.businesswire.com/news/home/20201204005214/en

    BUSINESSWIRE
    04 Dec 2020
    Share Share
    New England Journal of Medicine Ph2 Trial Evaluating Takeda’s TAK-620 Maribavir
    New England Journal of Medicine Ph2 Trial Evaluating Takeda’s TAK-620 Maribavir

    https://www.businesswire.com/news/home/20190924005143/en/New-England-Journal-Medicine-Publishes-Results-Phase/?feedref=JjAwJuNHiystnCoBq_hl-WBlLQO14j4QZPTyX5CYOnwC4VjN53jumZRlnzhBoBxGrCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3ltkRSnqzf6ourQGu_UA28CzZCGORvG0LE20YOvo49uqw==

    BUSINESSWIRE
    24 Sep 2019
    Share Share
    Top 10: Takeda’s late-stage pipeline will rely heavily on Shire drugs
    Top 10: Takeda’s late-stage pipeline will rely heavily on Shire drugs

    https://endpts.com/top-10-takedas-late-stage-pipeline-will-rely-heavily-on-shire-drugs-but-is-it-worth-62b/

    By Meiling ENDPTS
    31 Jul 2018
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-05-06

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search